Table 3.
PTSD and depressive symptom severity at baseline and at endpoint according to CAPS and BDI scores: efficacy analysis
| Outcome | Baseline mean (SD) | Endpoint mean (SD) | P | f |
|---|---|---|---|---|
| CAPS TOTAL* | 0.007 | 7.11 | ||
| Topiramate (n = 17) | 79.64 (12.03) | 21.85 (21.38) | ||
| Placebo (n = 14) | 64.33 (22) | 31.91 (28.22) | ||
| Reexperiencing symptoms (CAPS‐B)* | 0.04 | 4.08 | ||
| Topiramate (n = 17) | 24 (5.65) | 4.5 (5.27) | ||
| Placebo (n = 14) | 21.08 (6.76) | 7.91 (6.59) | ||
| Avoidance/numbing symptoms (CAPS‐C)* | 0.0001 | 15.46 | ||
| Topiramate (n = 17) | 32 (5.76) | 8.5 (9.81) | ||
| Placebo (n = 14) | 23.25 (11.25) | 16.25 (15.28) | ||
| Hyperarousal symptoms (CAPS‐D) | 0.47 | 0.52 | ||
| Topiramate (n = 17) | 23.64 (6.15) | 8.85 (8.61) | ||
| Placebo (n = 14) | 20 (8.33) | 8.75 (9.19) | ||
| CGI | 0.22 | 1.45 | ||
| Topiramate (n = 17) | 4.78 (0.57) | 1.5 (0.85) | ||
| Placebo (n = 14) | 4.75 (0.62) | 2.41 (1.78) | ||
| BDI | 0.45 | 0.55 | ||
| Topiramate (n = 17) | 21.28 (9.83) | 11.76 (9.86) | ||
| Placebo (n = 14) | 22.91 (11.5) | 17.75 (14.75) | ||
*P < 0.05 statistically significant difference.
CAPS, Clinician‐Administered Posttraumatic Stress Scale; CGI, Clinical Global Impression; BDI, Beck Depression Inventory.